- Home
- CLRO vs OSRH Comparison
CLRO vs OSRH Comparison
Compare CLRO & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLRO | OSRH |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 17.9M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLRO | OSRH |
|---|---|---|
| Price | $5.66 | $0.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 672.2K |
| Earning Date | 05-18-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | $2,905,805.00 |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.25 |
| 52 Week High | $16.50 | $1.24 |
Technical Indicators
Market Signals| Indicator | CLRO | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 27.96 |
| Support Level | $3.97 | N/A |
| Resistance Level | $7.14 | $0.45 |
| Average True Range (ATR) | 1.46 | 0.04 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 18.87 | 4.89 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.